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Hepatocyte growth factor (HGF) stimulates survival,
proliferation (1), adhesion (2) and migration (3) of malig-
nant plasma cells and is a potential contributor to the
bone disease of multiple myeloma (4). HGF is produced
by myeloma cells and by stromal cells in the bone mar-
row microenvironment, and thereby acts in an autocrine
or paracrine manner through its receptor c-Met (5–7). We
and others have previously shown that serum HGF levels
are elevated in myeloma patients compared with normal
controls, and associated with poor prognosis (8, 9).
HGF is secreted as a single chain precursor which is
proteolytically converted to its biologically active hetero-
dimeric form. The most potent activator is the factor XII-
related serine protease hepatocyte growth factor activator
(HGFA) (10, 11). HGFA is mainly secreted by the liver,
although extrahepatic expression has been reported in a
number of normal and tumour tissues (12). It circulates in
plasma as a single-chain 96-kDa pro-form, which is acti-
vated by thrombin in the presence of negatively charged
molecules to its 34-kDa active two-chain heterodimeric
form (13). The HGFA activity is regulated by the HGF
activator inhibitors (HAI)-1 and -2, reviewed in (12).
Tjin et al. (14) showed that myeloma cells express
HGFA and thereby proteolytically convert single chain
HGF into its active form. We aimed to examine the lev-
els of the activated form of HGFA in serum and bone
marrow plasma from myeloma patients, and to correlate
the serum levels with clinical stage, parameters of disease
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possible relationship between the concentrations of
HGFA and HGF.
Patients and methods
We examined serum samples drawn at diagnosis from 49
patients diagnosed with multiple myeloma in mid-Nor-
way between 1996 and 2005. We also examined bone
marrow plasma from the same patients when available
(n = 16). Serum and bone marrow plasma samples were
drawn before initiation of treatment and frozen at )80 C
until they were analyzed. In six patients, we also exam-
ined serum drawn at time of ﬁrst response, deﬁned
according to the EBMT⁄IBMTR⁄ABMTR criteria (15)
and at ﬁrst relapse, deﬁned as the time point where treat-
ment was re-introduced. Control samples were obtained
from 24 healthy volunteers. Because of limited quantities
of sample material, HGF was analyzed in only 20 of the
24 controls. Clinical information about the myeloma
patients was obtained retrospectively from the patient
records. Registered information was stage according to
Durie Salmon and International Scoring System (ISS),
type and concentrations of serum and urine M-compo-
nent, plasma cell percentage in bone marrow aspirate,
serum b2-microglobulin and overall survival. The study
protocol was approved by the Regional Medical Ethics
Committee and the study was performed according to
the declaration of Helsinki.
The median age of the myeloma patients (33 men and
16 women) was 65 yr (range 30–87 yr), and of the con-
trols (15 men and 9 women) was 68 yr (range 44–81 yr).
The patients were representative of the general myeloma
population with serum M-component of IgG type in 29
patients (59%), IgA in seven patients (14%), other Ig is-
otypes in three patients (6%), only light chain secretion
in nine patients (18%) and non-secretory myeloma in
one patient (2%). Twenty patients (41%) were in stage 1
according to ISS, 13 patients (26%) in stage 2 and 11
patients (22%) in stage 3; for ﬁve patients (10%), no
information was available.
We used a commercially available enzyme-linked
immunosorbent assay (ELISA) for the measurement of
activated HGFA (IBL, Gunma, Japan) in serum and
bone marrow plasma. The assay was performed accord-
ing to the manufacturer’s instructions. All samples were
run in duplicates. The standard curve was linear between
0.9 and 15 ng⁄mL, and samples were diluted to concen-
trations within this range. The intra-assay and interassay
variation coefﬁcients for this assay are 5.5% and 5.5%
at 6.5 ng⁄mL according to the manufacturer. Variation
coefﬁcients for our measurements were <10%.
HGF was measured with an ELISA from R&D systems
(Minneapolis, MN, USA). The assay was performed
according to the manufacturer’s instructions. All samples
were run in duplicates. The standard curve was linear
between 0.5 and 8 ng⁄mL. Because of limited quantities of
sample material, the measurements could not be repeated
and therefore samples with HGF concentrations lower
than 0.5 ng⁄mL and above 8 ng⁄mL were given the values
0.5 and 8 ng⁄mL. Variation coefﬁcients for our measure-
ments were <10%. Up to two freeze–thaw cycles of serum
did not affect the measured levels of HGF or HGFA.
SPSS Statistical Software version 14.0 was used for
statistic calculations (SPSS Inc, Chicago, IL, USA).
Comparisons between groups were performed by the
Mann–Whitney U-test. Correlations between two para-
meters were estimated by Spearman’s rank correlation
analysis. Survival analysis was conducted by the
Kaplan–Meier method, using median values as cut off.
The level of statistical signiﬁcance was set at P < 0.05.
P-values were two-tailed.
Results
Serum levels of activated HGFA in patients at the time
of diagnosis and in controls are shown in Fig. 1. The
median HGFA concentrations in myeloma and control
sera were 39.7 (range 6.2–450.0) and 17.6 ng⁄mL (range
4.8–280.6), respectively. The difference was statistically
signiﬁcant (P = 0.037). The median level of activated
HGFA in bone marrow plasma of myeloma patients was
6.1 ng⁄mL (range 3.5–30.0) (data not shown). Thus,
HGFA levels were lower in bone marrow plasma than in
serum. However, serum and plasma HGFA levels cannot
be directly compared, as measurement of levels in serum
will be 2–3 times higher than in plasma in this assay
according to the manufacturer and own validation exper-
iments (data not shown).
There was no correlation between the serum levels of
HGFA and disease stage according to ISS or Durie
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Figure 1 Serum concentrations of activated HGFA measured by
ELISA in 49 multiple myeloma patients and 24 age- and gender-
matched controls. Bars indicate median concentration.
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b2-microglobulin, percentage of plasma cells in the bone
marrow or overall survival (data not shown). The HGFA
levels did not covariate with disease activity in serial
measurements of serum drawn at diagnosis, remission
and relapse in six myeloma patients (data not shown).
The median HGF concentrations in myeloma and con-
trol sera were 2.5 (range 0.7–8.0) and 1.6 ng⁄mL (range
0.5–4.0), respectively (Fig. 2). The difference was statisti-
cally signiﬁcant (P < 0.001). The median HGF concen-
tration in bone marrow plasma was 8.0 ng⁄mL. There
was no correlation between the levels of HGFA and
HGF in serum (rs = 0.14, P = 0.26) or bone marrow
plasma (rs = 0.31, P = 0.38).
Discussion
HGF has a number of myeloma-relevant activities; how-
ever, it has to be converted to its heterodimeric form to be
biologically active. Urokinase-type plasminogen activator
(uPA), tissue plasminogen activator, factor XIIa and ma-
triptase have all been shown to activate single chain HGF
at low rates (11, 16–18). The most potent activator is, how-
ever, the factor XII-related serine protease HGFA, with
an HGF-converting potency of more than 1000 times that
of uPA (11). Tjin et al. (14) showed that myeloma cells
express HGFA, thereby activating HGF. We here demon-
strate for the ﬁrst time that HGFA exists in its activated
form in serum from myeloma patients, and that serum
concentrations are higher than in healthy controls. We
also found detectable activated HGFA in 16 of 16 samples
of bone marrow plasma from myeloma patients.
The role of HGFA in regulating HGF activity in
injured tissue is well established (12). Recent data sup-
port an important function of HGFA also in solid
tumours such as colorectal cancer (19) and glioblastoma
(20). Among lymphomas, the HGF receptor is predomi-
nantly expressed in diffuse large B-cell lymphoma
(DLBCL), and interestingly, DLBCL cells also express
HGFA, possibly activating HGF produced by macro-
phages in the tumour microenvironment (21).
The activity of HGFA is tightly regulated. Secreted as
an inactive single chain pro-form, cleavage by thrombin
is essential for its function. In a recent publication, the
kallikrein-related peptidases 4 and 5 were shown to have
HGFA-activating properties similar to thrombin (22).
The activity of HGFA is also controlled by the Kunitz
type serine protease inhibitors HAI-1 and HAI-2 (12).
It is possible that the myeloma cells directly contribute
to the elevated HGFA levels in serum of myeloma
patients. However, we found no correlation between the
serum HGFA concentration and disease stage or tradi-
tional markers of tumour burden. As we have measured
only the activated form of HGFA, the elevated levels in
myeloma patients might also mirror a higher degree of
activation of pro-HGFA in patients compared with con-
trols. The complex mechanisms regulating activation of
HGF in multiple myeloma, including a potential role for
the HGFA inhibitors HAI-1 and HAI-2, should be
addressed in further studies.
We found no correlation between serum levels of
HGFA and HGF. This is partly in disagreement with
Nagakawa et al. (23), who found a positive correlation
between serum levels of HGF and HGFA in patients
with untreated and advanced stage prostate cancer. How-
ever, the fact that we have measured total HGF, which
is both single chain HGF and the active heterodimer,
may obscure a positive correlation between HGFA and
active HGF.
In conclusion, activated HGFA is present at high
levels in serum and bone marrow of myeloma patients.
Although this study has obvious limitations because of
the relatively small number of study subjects, it clearly
demonstrates the presence of a necessary prerequisite for
activation of the HGF system in multiple myeloma. It
also points to the activation step of HGF as a possible
target for therapeutic intervention.
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